Real-time Estimate
Cboe BZX
10:13:26 2025-01-23 am EST
5-day change
1st Jan Change
2.320 USD
-1.28%
+2.41%
+45.03%
William Blair Downgrades Neuronetics to Market Perform From Outperform
August 13, 2024 at 07:44 am EDT
This article is reserved for members
Not a member ?
Free registration
Neuronetics, Inc. Announces Unaudited Revenue Results for Fourth Quarter and Full Year 2024
Jan. 13
CI
Neuronetics, Inc. Provides Earnings Guidance for the Full Year 2025
Jan. 13
CI
Neuronetics, Inc. completed the acquisition of Greenbrook TMS Inc. (OTCPK:GBNH.F) from Madryn Health Partners II (Cayman Feeder), LP, fund managed by Madryn Asset Management, LP, 1315 Capital II, L.P. fund managed by 1315 Capital, LLC, Greybrook Health Inc. and others for $0.58 million.
Dec. 08
CI
Neuronetics, Inc., Q3 2024 Earnings Call, Nov 12, 2024
Nov. 12
Earnings Flash (STIM) NEURONETICS Reports Q3 Revenue $18.5M
Nov. 12
MT
Neuronetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
Nov. 12
CI
Neuronetics, Inc. Provides Standalone Earnings Guidance for the Fourth Quarter and Full Year 2024
Nov. 12
CI
Neuronetics, Greenbrook Receive Interim Order for Special Meeting of Shareholders for Greenbrook
24-10-04
MT
Neuronetics, Inc. Expands Health Policies Enhance Tms Therapy Access for Adolescents and Adults
24-09-19
CI
William Blair Downgrades Neuronetics to Market Perform From Outperform
24-08-13
MT
Neuronetics Shares Slump as Q2 Results Fall Below Estimates; Merger Announcement
24-08-12
MT
Neuronetics, Inc., Q2 2024 Earnings Call, Aug 12, 2024
24-08-12
Neuronetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
24-08-12
CI
Earnings Flash (STIM) NEURONETICS Reports Q2 Revenue $16.5M, vs. Street Est of $18.7M
24-08-12
MT
Neuronetics, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2024
24-08-12
CI
Neuronetics, Inc. entered into a definitive arrangement agreement to acquire Greenbrook TMS Inc. (OTCPK:GBNH.F) from Madryn Health Partners II (Cayman Feeder), LP, fund managed by Madryn Asset Management, LP and others for $1 million.
24-08-11
CI
Neuronetics, Inc. Announces Aetna Policy Update Expands TMS Availability for Adolescents with Depression
24-07-22
CI
Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents
24-05-15
CI
William Blair Upgrades Neuronetics to Outperform From Market Perform
24-05-14
MT
Neuronetics, Inc., Q1 2024 Earnings Call, May 07, 2024
24-05-07
Earnings Flash (STIM) NEURONETICS Reports Q1 Revenue $17.4M
24-05-07
MT
Neuronetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
24-05-07
CI
Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2024
24-05-07
CI
Neuronetics, Inc. Announces the Publication of Significant Clinical Findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation
24-04-10
CI
Neuronetics, Inc. Announces John K. Bakewell, Joseph H. Capper and Dr. Wilfred E. Jaeger Not Stand for Reelection to the Board
24-03-28
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
STIM: Dynamic Chart
Neuronetics, Inc. is a commercial-stage medical technology company. The Company is focused on designing, developing and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The Company sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
More about the company
Last Close Price
2.350 USD
Average target price
2.667 USD
Spread / Average Target
+13.48%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1